Cesca Therapeutics Company Profile (NASDAQ:KOOL)

About Cesca Therapeutics

Cesca Therapeutics logoCesca Therapeutics Inc. is focused on the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is engaged in developing and manufacturing automated blood and bone marrow processing systems that enable the separation processing and preservation of cell and tissue therapy products. It focuses in three target markets to serve patients physicians and partners: cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking. The Company focuses on three areas: critical limb ischemia (CLI), acute myocardial infarction (AMI) and bone marrow transplant (BMT). The Company offers SurgWerks and VXP System Platform, and CellWerks Platform. Its products include AutoXpress (AXP) System, MarrowXpress (MXP) System, BioArchive System and Res-Q 60 BMC. It also provides cell manufacturing and banking services.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KOOL
  • CUSIP:
Key Metrics:
  • Previous Close: $3.98
  • 50 Day Moving Average: $3.84
  • 200 Day Moving Average: $3.54
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $11.76M
  • Outstanding Shares: 3,008,000
  • Beta: 0.16
Additional Links:
Companies Related to Cesca Therapeutics:

Analyst Ratings

Consensus Ratings for Cesca Therapeutics (NASDAQ:KOOL) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $1.50 (61.64% downside)

Analysts' Ratings History for Cesca Therapeutics (NASDAQ:KOOL)
Show:
DateFirmActionRatingPrice TargetDetails
8/1/2016Maxim GroupReiterated RatingHoldView Rating Details
9/21/2015HC WainwrightUpgradeNeutral -> Buy$2.00View Rating Details
(Data available from 8/27/2014 forward)

Earnings

Earnings History for Cesca Therapeutics (NASDAQ:KOOL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/15/2016        
2/16/2016Q216($0.07)($0.02)$4.32 million$3.29 millionViewListenView Earnings Details
11/16/2015Q116($0.06)($0.08)$3.71 million$2.80 millionViewListenView Earnings Details
9/17/2015Q415($0.11)($0.06)$3.70 millionViewListenView Earnings Details
6/23/2015Q315($0.08)($0.12)$4.00 millionViewListenView Earnings Details
2/12/2015Q215($0.08)($0.11)$4.08 million$4.60 millionViewN/AView Earnings Details
11/13/2014Q115($0.08)$3.60 million$3.70 millionViewN/AView Earnings Details
9/29/2014Q414($0.06)($0.09)$4.30 millionViewN/AView Earnings Details
5/15/2014($0.05)($0.07)ViewN/AView Earnings Details
2/14/2014Q214($0.10)$4.80 million$4.50 millionViewN/AView Earnings Details
11/14/2013Q1($0.14)ViewListenView Earnings Details
8/29/2013Q4 2013($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details
11/13/2012Q113$0.06$4.90 million$4.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cesca Therapeutics (NASDAQ:KOOL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cesca Therapeutics (NASDAQ:KOOL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cesca Therapeutics (NASDAQ:KOOL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2015Kenneth HarrisDirectorSell80,858$0.60$48,514.80View SEC Filing  
11/9/2015Kenneth HarrisDirectorSell48,468$0.60$29,080.80View SEC Filing  
11/6/2015Kenneth HarrisDirectorSell30,190$0.60$18,114.00View SEC Filing  
11/3/2015Kenneth HarrisDirectorSell10,510$0.60$6,306.00View SEC Filing  
11/2/2015Kenneth HarrisDirectorSell5,700$0.60$3,420.00View SEC Filing  
10/29/2015Kenneth HarrisDirectorSell8,632$0.60$5,179.20View SEC Filing  
9/2/2015Matthew T. PlavanCEOSell17,271$0.68$11,744.28View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cesca Therapeutics (NASDAQ:KOOL)
DateHeadline
bizjournals.com logoChinese stem-cell research company takes control of Rancho Cordova's Cesca Therapeutics (NASDAQ:KOOL)
www.bizjournals.com - August 26 at 5:42 PM
baystreet.ca logoCesca Therapeutics (KOOL) Jumps on Debt Question (NASDAQ:KOOL)
www.baystreet.ca - August 25 at 5:51 PM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Unregistered Sale of Equi (NASDAQ:KOOL)
biz.yahoo.com - August 25 at 5:51 PM
nasdaq.com logoCesca Therapeutics Announces Conversion of $12.5 Million in Senior Secured Debt to Equity (NASDAQ:KOOL)
www.nasdaq.com - August 25 at 10:55 AM
streetinsider.com logoCesca Therapeutics (KOOL) to Convert $12.5M in Senior Secured Debt to Equity (NASDAQ:KOOL)
www.streetinsider.com - August 25 at 10:55 AM
News IconAnalysts Valuations For Two Stocks: Cesca Therapeutics Inc (NASDAQ:KOOL), ACADIA Pharmaceuticals Inc ... - The Voice Registrar (NASDAQ:KOOL)
voiceregistrar.com - August 24 at 5:45 PM
News IconCesca Therapeutics Inc. (NASDAQ:KOOL) is raising $2.5 million in a registered direct stock offering - Inside Trade (NASDAQ:KOOL)
insidetrade.co - August 24 at 5:45 PM
News IconStock Moving Up in Session: Cesca Therapeutics Inc. (NASDAQ:KOOL) - Post News (NASDAQ:KOOL)
www.kentuckypostnews.com - August 23 at 10:18 AM
News IconMy Watchlist for Tuesday, August 23 (NASDAQ:KOOL)
ac-investor.blogspot.com - August 22 at 5:55 PM
News IconMy Watchlist for Tuesday, August 23 (NASDAQ:KOOL)
ac-investor.blogspot.com - August 22 at 5:55 PM
News IconMy Watchlist for Tuesday, August 16 (NASDAQ:KOOL)
ac-investor.blogspot.com - August 15 at 6:04 PM
live-pr.com logoCesca Therapeutics Inc. (KOOL) - Medical Equipment - Deals and Alliances Profile - New Market Study Published (NASDAQ:KOOL)
www.live-pr.com - August 9 at 6:03 PM
streetinsider.com logoCesca Therapeutics (KOOL) Enters $2.5M Common Stock Registered Direct Offering (NASDAQ:KOOL)
www.streetinsider.com - August 5 at 5:59 PM
News IconCesca Therapeutics Inc. (NASDAQ:KOOL) Issues Favorable 40-Month Follow-Up Results Of SurgWerks Feasibility Study (NASDAQ:KOOL)
wallstreetpr.com - August 5 at 5:59 PM
News IconHealthcare Stocks in Retreated Reviews- Cesca Therapeutics (NASDAQ:KOOL), INSYS Therapeutics (NASDAQ:INSY) - Seneca Globe (NASDAQ:KOOL)
www.senecaglobe.com - August 5 at 8:53 AM
bizjournals.com logoCesca Therapeutics raises $2.5 million in private placement of stock (NASDAQ:KOOL)
www.bizjournals.com - August 5 at 8:53 AM
benzinga.com logo20 Stocks Moving In Wednesday's Pre-Market Session - Benzinga (NASDAQ:KOOL)
www.benzinga.com - August 4 at 6:09 PM
News IconWhat's Cesca Therapeutics Inc. (NASDAQ: KOOL) Planning With Its SurgWerks? - Scibility Media (NASDAQ:KOOL)
scibilitymedia.com - August 4 at 6:09 PM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Fin (NASDAQ:KOOL)
biz.yahoo.com - August 4 at 6:09 PM
publicnow.com logoCESCA THERAPEUTICS ANNOUNCES PRICING OF $2.5 MILLION REGISTERED DIRECT OFFERING (NASDAQ:KOOL)
www.publicnow.com - August 4 at 6:09 PM
News IconClosed at the Highs for the Day (NASDAQ:KOOL)
www.fxstreet.com - August 4 at 8:57 AM
rttnews.com logoAXGN Making News, Milestone Events Lined Up For NBIX, Cesca Plays It Cool (NASDAQ:KOOL)
www.rttnews.com - August 4 at 8:57 AM
marketexclusive.com logoHere’s A Look At Two Promising CLI Companies And Their Near... (NASDAQ:KOOL)
marketexclusive.com - August 4 at 8:57 AM
News IconCool Upward Move for Cesca Therapeutics (KOOL); Teva Pharma (TEVA) Seal Half-Billion Dollar Deal for Allergan’s (AGN) Anda (NASDAQ:KOOL)
galaxystocks.com - August 3 at 6:11 PM
nasdaq.com logoCesca Therapeutics Announces Promising Results From 40-Month Follow-Up of Patients Enrolled in Critical Limb Ischemia Feasibility Study (NASDAQ:KOOL)
www.nasdaq.com - August 3 at 6:11 PM
rttnews.com logoCesca Therapeutics Inc. (KOOL) Is Up Sharply On Study Results (NASDAQ:KOOL)
www.rttnews.com - August 3 at 6:11 PM
streetinsider.com logoCesca Therapeutics (KOOL) Announces Positive SurgWerks Feasibility Study in CLI (NASDAQ:KOOL)
www.streetinsider.com - August 3 at 6:11 PM
bizjournals.com logoCesca Therapeutics shares jump on positive results from clinical study (NASDAQ:KOOL)
www.bizjournals.com - August 3 at 6:11 PM
streetinsider.com logoCesca Therapeutics (KOOL) Announces Positive SurgWerks Feasibility Study in CLI - StreetInsider.com (NASDAQ:KOOL)
www.streetinsider.com - August 3 at 9:06 AM
News IconCesca Therapeutics Announces Publication of Results on Use of Its Technology for Treatment of Non-Union Fracture (NASDAQ:KOOL)
www.pharmiweb.com - August 2 at 6:09 PM
streetinsider.com logoCesca Therapeutics (KOOL) Updates on FDA Review of SurgWerks IDE Supplement; Primary Endpoint Changed - StreetInsider.com (NASDAQ:KOOL)
www.streetinsider.com - August 2 at 10:41 AM
fortune.com logoPremarket Runners: Texas Roadhouse Inc(NASDAQ:TXRH), Cesca Therapeutics Inc(NASDAQ:KOOL) - Review Fortune (NASDAQ:KOOL)
reviewfortune.com - August 2 at 10:41 AM
streetinsider.com logoCesca Therapeutics (KOOL) Announces Publication of Positive Non-Union Fracture Data Utilizing Proprietary ... - StreetInsider.com (NASDAQ:KOOL)
www.streetinsider.com - August 2 at 10:41 AM
News IconCesca Therapeutics Inc (NASDAQ:KOOL): A Momentum Play With A Make Or Break Decision Near Term (NASDAQ:KOOL)
streetregister.com - August 1 at 5:43 PM
streetinsider.com logoCesca Therapeutics (KOOL) Updates on FDA Review of SurgWerks IDE Supplement; Primary Endpoint Changed (NASDAQ:KOOL)
www.streetinsider.com - August 1 at 10:38 AM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:KOOL)
biz.yahoo.com - August 1 at 6:11 AM
finance.yahoo.com logo6:07 am Cesca Therapeutics updates on FDA review of the Investigational Device Exemption Supplement for SurgWerks CLI pivotal trial (NASDAQ:KOOL)
finance.yahoo.com - August 1 at 6:07 AM
finance.yahoo.com logoCesca Therapeutics Provides Update on FDA Review of Investigational Device Exemption Supplement for SurgWerks™ CLI Pivotal Trial (NASDAQ:KOOL)
finance.yahoo.com - August 1 at 6:00 AM
fortune.com logoPre-Market Stock's Buzzers: Kingtone Wirelessinfo Solutions Hldg Ltd(NASDAQ:KONE), Cesca Therapeutics Inc ... - Review Fortune (NASDAQ:KOOL)
reviewfortune.com - July 28 at 6:03 PM
News IconTopsy-Turvy, Volatile Session (NASDAQ:KOOL)
www.fxstreet.com - July 27 at 8:44 AM
4-traders.com logoAlimera Sciences : Five Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements (NASDAQ:KOOL)
www.4-traders.com - July 27 at 8:44 AM
rttnews.com logoCesca Therapeutics Inc. (KOOL) Has Surged To Nearly A 5-Month High (NASDAQ:KOOL)
www.rttnews.com - July 27 at 8:44 AM
benzinga.com logo18 Biggest Mid-Day Gainers For Tuesday - Benzinga (NASDAQ:KOOL)
www.benzinga.com - July 26 at 6:06 PM
ftsenews.co.uk logoNew Broker Ratings For Cesca Therapeutics Inc. (KOOL) - FTSE News (NASDAQ:KOOL)
www.ftsenews.co.uk - July 22 at 8:51 AM
News IconAre Analysts Bullish Cesca Therapeutics Inc (NASDAQ:KOOL) After Last Week? - Press Telegraph (NASDAQ:KOOL)
presstelegraph.com - July 18 at 6:03 PM
News IconCesca Therapeutics Incorporated (NASDAQ:KOOL) Shorted Shares Decreased By 31.42% - Press Telegraph (NASDAQ:KOOL)
presstelegraph.com - July 15 at 9:53 AM
biz.yahoo.com logoCESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib (NASDAQ:KOOL)
biz.yahoo.com - July 12 at 6:05 AM
News IconCesca Therapeutics Incorporated (NASDAQ:KOOL) Sellers Covered 31.42% of Their Shorts - Press Telegraph (NASDAQ:KOOL)
presstelegraph.com - July 11 at 5:54 PM
News IconHow Many Cesca Therapeutics Inc (NASDAQ:KOOL)'s Analysts Are Bullish? - Engelwood Daily (NASDAQ:KOOL)
www.engelwooddaily.com - July 10 at 10:09 AM
fiscalstandard.com logoBroker Outlook For Cesca Therapeutics Inc. (KOOL) - Fiscal Standard (NASDAQ:KOOL)
www.fiscalstandard.com - July 8 at 5:59 PM

Social

Cesca Therapeutics (NASDAQ:KOOL) Chart for Saturday, August, 27, 2016


Last Updated on 8/27/2016 by MarketBeat.com Staff